Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Radium ra-223 dichloride
Drug ID BADD_D02586
Description Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin. Xofigo is indicated in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant. The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm.
Indications and Usage Used in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant.
Marketing Status approved; investigational
ATC Code Not Available
DrugBank ID DB08913
KEGG ID Not Available
MeSH ID Not Available
PubChem ID Not Available
TTD Drug ID Not Available
NDC Product Code 50419-208
UNII RJ00KV3VTG
Synonyms Not Available
Chemical Information
Molecular Formula Not Available
CAS Registry Number 444811-40-9
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bladder cancer recurrent16.08.01.003; 20.03.04.005--
Lung carcinoma cell type unspecified recurrent16.19.02.005; 22.08.01.018--
Metastases to abdominal cavity07.21.03.006; 16.22.02.010--
Metastases to adrenals05.01.04.007; 16.22.02.012--
Metastases to bone15.09.03.006; 16.22.02.005--
Metastases to lymph nodes01.09.01.015; 16.22.02.006--
Metastases to pleura16.22.02.022; 22.05.04.002--
Prostate cancer stage IV16.25.01.007; 21.04.02.010--
Anaemia of malignant disease01.03.04.003--
Metastases to bone marrow01.05.01.022; 16.22.02.013--
Metastases to meninges16.22.02.003; 17.02.10.012--
Postrenal failure20.01.03.021--
Metastases to soft tissue15.09.03.020; 16.22.02.024--
Bladder tamponade20.02.02.024; 24.07.01.064--
Hormone-refractory prostate cancer16.25.01.004; 21.04.02.007--
Metastases to pelvis16.22.02.021; 21.07.04.008--
Spinal pain08.01.08.030; 15.02.01.008; 17.10.01.020--
Abdominal lymphadenopathy01.09.01.020; 07.11.01.018--
Bone marrow infiltration01.05.01.018--
Internal haemorrhage24.07.01.072--
Critical illness08.01.03.065--
Bone marrow tumour cell infiltration01.13.01.005; 16.21.01.005--
Gait inability08.01.02.011; 17.02.05.069--
Illness08.01.03.091--
Metastases to gastrointestinal tract07.21.03.010; 16.22.02.034--
Metastases to spinal cord16.22.02.042; 17.10.01.028--
Myelosuppression01.03.03.015--
Physical deconditioning08.01.03.096--
The 5th Page    First    Pre   5    Total 5 Pages